MiNK Therapeutics, Inc. (INKT) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Mink Therapeutics (INKT) Q1 2026: 90-Patient ARDS Trial Launch Signals Pivotal Data Path
May 15, 2026
-
Mink Therapeutics (INKT) Q4 2025: Operating Costs Down 40% as Pipeline Advances to Randomized Trials
March 31, 2026
-
Mink Therapeutics (INKT) Q3 2025: 700% Equity Surge Fuels Pipeline Expansion in INKT Cell Therapy
November 14, 2025
-
Mink Therapeutics (INKT) Q2 2025: 30% Burn Reduction Extends Runway as INKT Platform Delivers Durable Responses
August 14, 2025